航空航天医学杂志 <link type="text/css" rel="stylesheet" href="../../Themes/WebStyle/Style.css">

西格列汀联合二甲双胍治疗初发2型糖尿病的疗效观察

作者： style="text-align: center font-family: 宋体 font-size: 10.5pt ">冯晓荣 style="text-align: center font-family: 宋体 font-size: 10.5pt "> style="text-align: center font-family: 宋体 font-size: 10.5pt ">郭晓静 style="text-align: center font-family: 宋体 font-size: 10.5pt "> style="text-align: center font-family: 宋体 font-size: 10.5pt ">马波

单位：西安航天总医院

关键词：西格列汀二甲双胍初发2型糖尿病

分类号：R587.2

出版年,卷(期):页码：2015,26(11):1072-1073

摘要：

目的观察西格列汀联合二甲双胍治疗初发2型糖尿病的疗效及安全性。方法将60例初发2型糖尿病随机分为两组，治疗组30例，治疗组：二甲双胍+西格列汀。对照组：单用二甲双胍。12周后比较两组患者治疗前后空腹血糖（FBG）、餐后2小时血糖（2hPG）、糖化血红蛋白（HbA1C）、体重指数（BMI）的变化。结果治疗12周后，治疗组与对照组的FBG、2hPG、HbA1C、BMI均下降，但治疗组较对照组各项指标显著下降，无明显不良反应。结论西格列汀联合二甲双胍可有效控制2型糖尿病患者血糖，降低HbA1C，减少体重增加的风险。

Objective To investigate the efficacy of dipeptidyl peptidase-4 inhibitor-sitagliptin in newly diagnosed patients with type II diabetes. Methords 60 type II diabetes in newly diagnosed patients were rangdomly divided into 2 groups,experimental group and control group.experimental group of 30 patients,the patients in experimental group were given sitagliptin and metformin，the patients in control group were only given metformin. 12 weeks later，the indications FBG,2hPG,HbA1C,BMI were tested to see if there is any change. Results After 12 weeks，The levels of FBG,2hPG，HbA1C，BMI were obviously descendent(P<0.05)，but the experimental group decreased significantly compared with the control group of indicatous.No significant adverse reactions. Conclusion Sitagliptin and metformin can effectively control the type II diabetes glucose and decreasing glycated hemoglobin,reducing the risk of weight gain

基金项目：

作者简介：

参考文献：

［1］Holman RR.The Treat-to-Target Trial：randomized addition of glargine or human NPH to oral therapy of type 2 diabetes［J］.Diabetes Res Clin Pract，1998,40（suppl 1）:S21-S25.

［2］K.Aaboe.Twelve weeks treatment with the DPP-4 inhibitor，sitagliptin，prevents degradation of people YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus［J］.Diabetes，Obesity and Metabolism，2010,4（12）323-332.

［3］Duttaroy A,Voelker F,Merriam K,et al.The DPP-4 inhibitor vildagliptin increases pancreatic beta cell neogenesis and decrease apoptosis［J］.Diabetes，2005,54，（suppl 1）A141.

［4］Greutzfeldt W.The entero-insular axis in type 2 diabetes incretins as therapeutic agents［J］.Exp Clin Endocrinol Diabetes,2001,109(suppl 2)288-303.

［5］Setter SM,Iltz JL,Thams J,et al.Metformin hydrochloride in the treatment of type 2 diabetes mellitus：a clinical review with a focus on dual therapy［J］.Clin Ther,2003,25(12):2991-3026.

［6］Raz I,Hanefeld M,Xu L,et al.Efficacy and safty of the dipeptidyl peptidase-4 inhibitor sitaglipin as monotherapy in patients with type 2 diabetes mellitus［J］.Didbetolgia,2006,49(11):2546-2571.

（收稿日期：2015-04-12）

服务与反馈：

【文章下载】【加入收藏】